UNSPSC 51171980: Velaglucerase alfa

This classification denotes an enzyme replacement preparation with the molecular formula C2532H3854N672O711S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23HYE36B0I, more generally known as velaglucerase alfa. European Medicines Agency schedules velaglucerase alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31010. The term VELAGLUCERASE ALFA is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 3, 2008, list 60.

Most nations schedule Velaglucerase alfa under HS 35079000 and SITC 51691. SMILES:. As of Q4 2014, VELAGLUCERASE ALFA remains the US FDA Preferred Term for this commodity.. Velaglucerase alfa bears US NLM identifiers UMLS ID C2919267 and NCI Concept Code C87735.

UNSPSC 51171980 Velaglucerase alfa is a Commodity code that represents a specific pharmaceutical product, but the recent state and local solicitations posted under this code do not reflect procurement of velaglucerase alfa itself. Instead, the tagged opportunities span drug testing services, pharmacy benefit program design, and generic pharmaceutical supply agreements—none of which align with velaglucerase alfa, a specialized enzyme replacement therapeutic for Gaucher disease. The code shows a substantial mismatch between its nominal scope and what is actually being solicited under it in the state and local market right now. State and local governments do not appear to be actively procuring velaglucerase alfa as a standalone pharmaceutical product through posted opportunities.

The three recent opportunities tagged to this code reflect broader pharmaceutical and drug-testing services. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with optional renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, distributed through authorized wholesalers to state and local government facilities. The issuing bodies span state health agencies, county corrections departments, and regional cooperative purchasing vehicles. The geographic activity is concentrated in Texas and Minnesota, with participation from Oregon through MMCAP. This code does not represent an active procurement category for the specific therapeutic product its name suggests; opportunities appear to be miscoded or represent administrative tagging errors rather than genuine demand for velaglucerase alfa.